Navigation Links
Epilepsy Drugs Can Enhance Risk of Birth Defects

Epilepsy is a chronic neurological disorder in which misfiring electrical impulses in the brain lead to seizures. About 2.3 million Americans have epilepsy, and more than a million are female. //Pregnant women who take anti-epileptic medications face a significant risk that their children will have problems ranging from congenital defects to slow development.

A new study adds to growing evidence that many commonly prescribed anti-epileptic drugs carry this risk, but the researchers caution that not taking the anti-seizure drugs could be even more harmful. Dean and his colleagues studied 160 mothers who were undergoing treatment with various antiepileptic drugs (AEDs) and who gave birth between 1977 and 2001.

Dean says that previous research had also shown a relatively high risk of problems seen in children exposed to AEDs while in the womb. He adds, however, that the drugs taken by the mothers in this study belong to the older generation of AEDs, and that that some small studies have suggested the newer generation of AEDs may be safer.
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drug Helps Diabetic Nerve Damage
5. Epilepsy Drug May Relieve Chronic Headaches
6. More Complications Seen In Women With Epilepsy
7. Epilepsy Drugs Found To Lead To Bone Loss
8. Another Use For Epilepsy Drugs
9. Epilepsy Patients Could Benefit From Pacemakers
10. Early Surgery For Treatment Of Epilepsy Questioned
11. Epilepsy Drug Valproate and Lamotrigine Linked To Malformed Fetus
Post Your Comments:
(Date:7/25/2008)... New program delivers immediate co...[24-hour telephone access to language interpreters...g multilingual solutions. , ...LLE® http://www.lle-inc.com/index.html [(Lan...ider of interpretation, translation, and language ...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
(Date:7/24/2008)...TON-SALEM, N.C. Researchers at Wake Forest Unive...-standing clinical belief that the hepatitis C vir...restore itself after HIV patients are treated with..., Hepatitis C (HCV) infection is more serious in...e, according to the Centers for Disease Control. I...
(Date:7/24/2008)...UTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 ... to report its 2008 second quarter and,year-to-dat...second quarter,and year-to-date financial results ...ding hours., The company will host a conference c...m. Eastern Time) on Tuesday, July 29, 2008. ev3,ma...
Breaking Medicine News(10 mins):Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
... manufacturing computer chips. Now, the mega giant...thcare companies’ towards providing quality health...n others have joined hands to enable high-end heal...ntinua Health Alliance, led by Intel will seek to ...
...mputed tomography (CT), magnetic resonance imaging...he newly developed multi-modal contrast agent – Re...na-Champaign says. Use of these new agents may, i...sis and treatment of cancer, according to Kenneth ...
...he class X examination - a feat no girl of her vil...e, some 150 km from the state capital of Bhubanesw...mers. It does not have a school. Jharana Sahu use...ery day to study at a high school in nearby Kalupu...
... interact physically in a biochemical partnership ...ssels. // The study was conducted by researchers ...ne and Queen's University, Ontario, Canada and rep...dicine. The COX enzymes are well-known for their ...
Other Medicine News:Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 2Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 3Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 4Health News:New Role of COX Enzymes Discovered 2
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
... into the body more easily than any comparable sco...ching the lower pole calyces. Its smooth, lubricio...on of both scope and instruments. And its patented...us tip, and active secondary deflection deliver co...
...Ureteroscope permits direct visualization and acce... little or no dilation.,A tight bend radius and ...renal access, including the lower pole calyces. Du...reter and the renal pelvis. The 6.75 beveled tip f...
Smooth, contoured standard obturator provides less traumatic insertion through the urethra and into the bladder.
Electrohydraulic Lithotripsy Probe for AEH-4
Medicine Products: